Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles via Google Scholar Articles by Rosack, J. Search for Related Content

Company Agrees to Give Reminyl New Name

The new name, Razadyne, came in response to FDA concerns about the drug's confusion with Amaryl, used to treat diabetes.

Ortho-McNeil Neurologics Inc., a division of Johnson and Johnson Inc., announced last month that it has completed a "re-branding" of the acetyl-cholinesterase inhibitor galantamine hydrobromide. The medication, originally branded as Reminyl, will now be marketed as Razadyne. The extended-release formulation is Razadyne ER.

The company initiated the name change in October 2004 after FDA safety officials voiced concerns regarding several reports of prescribing and dispensing errors between Reminyl and a similarly named drug, Amaryl (glimepiride),

Galantamine is indicated for the treatment of mild to moderate Alzheimer's disease, while glimepiride is indicated for the treatment of diabetes. Glimepiride is marketed by Sanofi-Aventis (Psychiatric News, December 3, 2004).

The FDA approved the immediate-release formulation of galantamine in February 2001, and the extended-release formulation in December 2004.

According to Ortho-McNeil, about 2 million patients have been treated with galantamine. According to drug adverseevent reports submitted to the FDA and the U.S. Pharmacopoeia, a few prescriptions for Reminyl have been incorrectly written, interpreted, labeled, or filled, leading to confusion between Reminyl and Amaryl. The accidental administration of Amaryl to Alzheimer's patients who did not have diabetes mellitus resulted in serious events, including severe hypoglycemia and, in two cases, death.

"Through ongoing discussions with the FDA," said Joseph Hulihan, M.D., vice president of medical affairs at Ortho-McNeil Neurologics Inc., in a prepared statement, "we agreed that the best way to avoid future dispensing errors was to change the name of Reminyl, which came onto the market nearly six years after Amaryl."

Razadyne ER will be available in pharmacies sometime this month, and the immediate-release formulation will be available beginning in July.

Psychiatrists and others with concerns or reports of medication errors related to Reminyl and Amaryl should contact Ortho-McNeil Neurologics Inc. at (800) 526-7736, the company said.

Additional information is posted online at <www.RAZADYNE.com>.

Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles via Google Scholar Articles by Rosack, J. Search for Related Content

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us